Succinylcholine: Difference between revisions
(Created page with "==Contraindications== 1) Known hyperK (current) 2) Massive burns >10% BSA (>4dys-healed) 3) Massive crush injuries (>4dys-healed) 4) Denervation* (>4dys-...") |
(→Source) |
||
| Line 37: | Line 37: | ||
==Source == | ==Source == | ||
2/06 DONALDSON (Adapted from Rosen) | 2/06 DONALDSON (Adapted from Rosen) | ||
Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis. | Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis. | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Airway/Resus]] | |||
Revision as of 04:38, 13 March 2011
Contraindications
1) Known hyperK (current)
2) Massive burns >10% BSA (>4dys-healed)
3) Massive crush injuries (>4dys-healed)
4) Denervation* (>4dys-6mo)
5) Neuromuscular dz** (indefinite)
6) Intra-abdominal sepsis (>5dys-resolution)
7) Increased ICP (may use w/ defacic dose)
(From-To)
- CVA (in particular those with residual deficits), spinal cord injury
- ALS, MS, skeletal muscle myopathies, cholinesterase def, h/o malignant hyperthermia
-no evidence to support contraindication in penetrating eye injuries-
N.B. Myasthenia Gravis- theoretically need more succ to induce vs nondepolarizing agents which have a prolonged effect.
This is 2/2 to lack of post-synaptic receptors, i.e. succ cannot potentiate a reaction 2/2 too few receptors.
Vs. it takes few "molecules" of roc/vec to block the few remaining functioning receptors.
Overall, most practitioners tend to avoid succ in all patients with possible neuromuscular disease.
Source
2/06 DONALDSON (Adapted from Rosen)
Levitan, R. Annals of EM. Vol 45, Issue 2. Safety of succinylcholine in myasthenia gravis.
